MedTrace Logo

Zinc Supplementation on Cellular Immunity in Thalassemia Major

NCT03117192 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2017-04-17

No results posted yet for this study

Summary

Randomized controlled trial was conducted in post-splenectomy patients aged \>12 years. Subjects are randomly assigned to two groups (zinc and placebo). 1.5 mg/kg/day (max 50 mg/day) of Zinc is administered.

Conditions

Interventions

DRUG

Zinc Sulfate

Zinc supplementation in syrup form

DRUG

Sucrose Syrup

Sucrose as placebo, with same taste and consistency as zinc

Sponsors & Collaborators

  • Fakultas Kedokteran Universitas Indonesia

    lead OTHER

Principal Investigators

  • Teny T Sari, M.D., PhD · Faculty of Medicine University of Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-01
Primary Completion
2014-02-01
Completion
2014-02-01

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03117192 on ClinicalTrials.gov